Department of Pathology and Cell Biology, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA.
Department of Pathology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA.
Br J Cancer. 2014 Jun 10;110(12):2945-54. doi: 10.1038/bjc.2014.245. Epub 2014 May 13.
The miRNA deregulation is commonly observed in human malignancies, where they act as tumour suppressors or oncogenes. Despite the association of several miRNAs with bladder cancer, little is known about the miRNAs that contribute to bladder cancer progression from non-muscle invasive (NMI) to muscle-invasive (MI) disease.
We first profiled the expression of miRNAs and mRNAs in a cohort of urothelial carcinomas and further characterised the role of miR-126 in invasion, as it emerged as the most downregulated miRNA between MI and NMI tumours.
We found that restoration of miR-126 levels attenuated the invasive potential of bladder cancer cells. Mechanistically, we identified the role of miR-126 in invasion through its ability to target ADAM9. Notably, a significant inverse correlation between miR-126 and ADAM9 expression was observed, where ADAM9 was upregulated in MI bladder cancer cells. While knockdown of ADAM9 attenuated the invasiveness of cells with low miR-126 levels, experimental upregulation of ADAM9 recapitulated the invasive phenotype. Furthermore, ADAM9 expression assessed by immunohistochemistry significantly correlated with poor prognosis in patients with urothelial carcinoma.
In this study we describe the role of miR-126 in bladder cancer progression, identifying miR-126 and ADAM9 as potential clinical biomarkers of disease aggressiveness.
miRNA 失调在人类恶性肿瘤中很常见,它们可以作为肿瘤抑制因子或癌基因发挥作用。尽管有几种 miRNA 与膀胱癌相关,但对于促进膀胱癌从不肌肉浸润(NMI)向肌肉浸润(MI)疾病进展的 miRNA 知之甚少。
我们首先对一组尿路上皮癌中的 miRNA 和 mRNAs 的表达进行了分析,并进一步研究了 miR-126 在侵袭中的作用,因为它是 MI 和 NMI 肿瘤之间下调最明显的 miRNA。
我们发现恢复 miR-126 水平可减弱膀胱癌细胞的侵袭潜力。从机制上讲,我们发现 miR-126 通过靶向 ADAM9 发挥其在侵袭中的作用。值得注意的是,miR-126 和 ADAM9 表达之间存在显著的负相关,MI 膀胱癌细胞中 ADAM9 上调。虽然 ADAM9 的敲低减弱了低 miR-126 水平细胞的侵袭性,但 ADAM9 的实验上调再现了侵袭表型。此外,免疫组织化学评估的 ADAM9 表达与尿路上皮癌患者的不良预后显著相关。
在这项研究中,我们描述了 miR-126 在膀胱癌进展中的作用,确定 miR-126 和 ADAM9 是疾病侵袭性的潜在临床生物标志物。